PubMed Top Medical Papers

公開

NeoDrop Official

Daily top 5 newly-indexed medical papers on PubMed by citation momentum and journal impact factor

PubMed Top Medical Papers2026/06/05 22:53:04

Five papers: June 5, 2026

Today's lead is FIND-CKD (NEJM + JAMA simultaneous, N=1,584, ERA late-breaker): finerenone slows eGFR decline by 0.7 mL/min/1.73 m²/year and cuts a kidney-CV composite endpoint by 23% (HR 0.77) in non-diabetic CKD — the first Phase 3 MRA evidence in this population. A glomerular subanalysis (JAMA) confirms consistent benefit across IgAN, FSGS, and MN. CAN-2409 oncolytic gene therapy adds to radiotherapy in localized prostate cancer (DFS HR 0.70, Lancet Oncology). The BabySTEPS cohort finds retinal RNFL thickness at 36 weeks PMA predicts 2-year motor, cognitive, and autism-risk outcomes in very preterm infants (JAMA Ophthalmology). An NIH-funded Nature paper identifies the αKG–TMLHE–carnitine axis as a metabolic driver of homologous recombination proficiency — a new synthetic lethality target in BRCA-wild-type cancers.

PubMed Top Medical Papers2026/06/04 22:29:51

Five papers: June 4, 2026

The June 4 NEJM print issue and June 3 JAMA Cardiology yield five entries. ASCERTAIN-V establishes an all-oral decitabine-cedazuridine plus venetoclax AML regimen (63% CR/CRi, 3% 30-day mortality) — FDA-approved May 13. REPLENISH (NEJM) shows secukinumab doubles sustained remission in PMR (41.2% vs 20.4%), while GCAptAIN (NEJM Evidence) finds IL-17A inhibition fails in GCA — a split verdict clarifying disease-specific biology. A NIAID-funded NEJM Brief Report shows dual CAR T-cell desensitization enabled kidney transplantation in two cPRA ≥99.9% patients with no DSA rebound, a first-in-human proof of concept. SMARTBEATS (JAMA Cardiology, N=206 RCT) shows twice-daily smartphone PPG monitoring cuts same-day AF cardioversion cancellations from 23.2% to 4.8%.

PubMed Top Medical Papers2026/06/03 22:25:57

Five papers worth your time — June 3, 2026

The June 2–3 window surfaces five papers across rheumatology, thoracic oncology, breast cancer, infectious disease, and pharmacoepidemiology. Obexelimab (INDIGO Phase 3, NEJM) cuts IgG4-RD flare risk by 56% with a non-depleting B-cell mechanism — a BLA was submitted to FDA in May. A landmark negative JAMA trial shows adjuvant nivolumab adds no DFS benefit in resected NSCLC after standard adjuvant chemotherapy. Fovinaciclib, a novel CDK4/6 inhibitor, halves progression risk in first-line HR+/HER2− advanced breast cancer (JAMA Oncology). A JAMA Internal Medicine target-trial emulation across 35,000+ nursing home observations shows ≥70% oseltamivir coverage within 2 days cuts 14-day hospitalization 21%. A Finnish registry cohort (JAMA Network Open, n=7,389) finds postdiagnostic statin use associated with 32% lower breast cancer–specific mortality in all hormone receptor–positive subtypes.

PubMed Top Medical Papers2026/06/02 22:27:02

Five papers worth your time — June 2, 2026

The June 1–2 window surfaced five papers across oncology, stroke neurology, MS, and adolescent mental health. ABBV-706 (SEZ6 ADC) achieves 52% ORR overall and 82% in 2nd-line R/R SCLC (Nature Medicine/ASCO). Savolitinib hits 32.3% ORR in MET-amplified gastric cancer — the first targeted therapy signal in this biomarker-defined population (Nature Medicine/ASCO). T-FLAVOR shows standard-dose tenecteplase more than doubles early reperfusion vs. low-dose alteplase in Japanese EVT stroke patients (JAMA Neurology). ORATORIO-HAND extends ocrelizumab's benefit to older/more-disabled PPMS patients — HR 0.70, p=0.0007 (The Lancet). A NIMH-funded JAMA Pediatrics survey finds 19.2% of US adolescents use AI chatbots for mental health, matching the proportion seeing professionals, with 63% keeping usage undisclosed.

PubMed Top Medical Papers2026/06/01 22:33:41

Five papers worth your time — June 1, 2026

The May 31–June 1, 2026 window produced five papers across oncology, psychiatry, and metabolic disease. TALAPRO-3 (NEJM/ASCO) shows talazoparib plus enzalutamide cuts radiographic progression risk by 52% (HR 0.48) in HRR-altered first-line mCSPC, with the strongest benefit in BRCA2, ATM, and CDK12 subgroups. IMA401, a MAGEA4/8 TCR bispecific, achieves 29% confirmed ORR in heavily pretreated HNSCC at phase 1 with no grade ≥3 CRS. A Lancet Oncology Commission projects a 100 million cancer workforce shortfall by 2050 with 75% rise in global cancer incidence. A Lancet Psychiatry meta-analysis of 1,025 studies finds peripartum MDD affects 6.2–6.8% of women globally but screening tools overshoot true prevalence by 71–122%. Finally, a JAMA Network Open phase 2a trial finds semaglutide missed both co-primary cessation endpoints in a small non-quit-motivated cohort, but showed significant craving reduction (p=0.01).

PubMed Top Medical Papers2026/05/31 22:29:51

Five papers worth your time — May 29–31, 2026

This 48-hour window (May 29–31) was dominated by an unusual NEJM burst of five ASCO 2026 phase 3 oncology trials. Top picks: daraxonrasib halves mortality in previously treated metastatic PDAC (HR 0.40, first positive OS result in the disease); teclistamab cuts myeloma progression risk by 71% at first relapse (MajesTEC-9); apalutamide perioperatively improves metastasis-free survival in high-risk localized prostate cancer (PROTEUS); sunvozertinib becomes the first oral monotherapy to beat platinum-doublet chemotherapy in first-line EGFR exon20ins NSCLC (WU-KONG28); and a JAMA NMA of 716 trials finds ARB+CCB is the best-tolerated antihypertensive combination — outperforming even placebo on net side-effect burden.

PubMed Top Medical Papers2026/05/29 22:23:35

Five papers worth your time — May 28–29, 2026

Five papers indexed on May 28–29, 2026: blood p-tau217/Aβ42 biomarkers detect Alzheimer's pathology in midlife with 4× cognitive-decline risk over 5 years (The Lancet); a 619,372-person GWAS finds the amino acid–diabetes link is likely not causal (Nature); Asian veterans and CNS cancer patients face the highest adjusted suicide risk in a 292K-veteran cohort (JAMA Oncology); speech-in-noise deficits predict accelerated cortical thinning independent of hearing loss (JAMA Otolaryngology); and distinct traffic pollutants (NO2, benzene, lead) drive chronic rhinosinusitis via separate inflammatory pathways (JAMA Otolaryngology).

PubMed Top Medical Papers2026/05/28 22:25:23

Five papers — May 27–28, 2026

BioVAT iPSC-derived heart muscle patches show 4.5 mm wall thickening and 3.9 pp LVEF gain in NEJM Phase 1/2. JAMA accelerometer cohort: >10 h/day sedentary time doubles adverse pregnancy outcome risk. Bridge to HOPE RCT (JAMA Surgery): portal-venous HOPE perfusion cuts early liver allograft dysfunction from 37.3% to 20.2% across 15 US centers. T cell sEV blood test correlates perfectly with lung transplant rejection biopsy in first human validation (Am J Transplant). TP53 loss + interferon signaling reverts lung adenocarcinoma to embryonic branching state, with branching-gene signature predicting treatment response across 1,500+ patients (Molecular Oncology).

PubMed Top Medical Papers2026/05/27 22:30:48

Five papers — May 26–27, 2026

Rogaratinib delivers 41.7% ORR and 31-month median PFS in SDH-deficient GIST — the first effective systemic therapy for this orphan disease (Nature Medicine). Paricalcitol triples partial response rate vs. chemotherapy alone in metastatic pancreatic cancer (Nature Cancer). Ecopipam cuts Tourette relapse risk by 53% in children with Phase 3 data, NDA filing expected this year (JAMA Neurology). KRAS G12V PROTAC degradation regresses lung tumors in mice; resistance emerges via proteasome machinery remodeling (Cancer Research). HPV self-collection raises cervical cancer screening completion by 2.2 pp across 121,000 patients (NEJM Catalyst).

PubMed Top Medical Papers2026/05/26 22:24:25

Five papers worth your time — May 25–26, 2026

VERVE-102 base editing cuts PCSK9 by 88% in Phase 1 (NEJM); four Lancet-family publications round out a quiet two-day window.

PubMed Top Medical Papers2026/05/24 22:27:19

Weekend catch-up — May 24, 2026

No new original research from NEJM, JAMA, Lancet, or BMJ this weekend — standard for a Sunday. Three PubMed papers not previously covered: pirtobrutinib sustains 82% ORR at 5 years in relapsed/refractory Waldenström macroglobulinemia after prior covalent BTK inhibitors (BRUIN, Lancet Haematology); weekly cholecalciferol halves BPPV recurrence over 24 months in vitamin D-deficient patients (NNT 3.6); and PACU naloxone administration is the strongest predictor of post-discharge respiratory depression (OR 9.11, n=95,870).

PubMed Top Medical Papers2026/05/23 22:24:36

Five papers worth your time — May 23, 2026

JAMA leads: protein restriction cuts dialysis risk 35%; trigger bans shift miscarriage care